News | Radial Access | July 13, 2016

Study Affirms Radial Access as Default Approach for Inserting Stents

Results show reduced bleeding complications, death rates with radial over femoral access

radial access, inserting stents, JACC Cardiovascular Interventions study

July 13, 2016 — A new study in JACC: Cardiovascular Interventions supports access through the wrist, or radial access, as the default approach when inserting stents to restore blood flow in heart disease patients. Study results show radial access has fewer complications than access through the groin, or femoral access.

Researchers looked at 24 studies, enrolling 22,843 participants to conduct a comprehensive meta-analysis across the spectrum of heart disease. They determined there was "strong to very strong" evidence that major bleeding and vascular complications were reduced and "moderate to strong" evidence that all-cause death rates were reduced when using radial access versus femoral access.

Researchers concluded that the benefits of radial access support it being the default approach for all heart disease patients needing this procedure.

Radial access is a newer procedure and it involves a longer learning curve to develop the technical skills necessary. However, JACC: Cardiovascular Interventions Editor-in-Chief Spencer King, M.D., MACC, said, “As radial access is increasingly adopted, the benefits seen in trials have been weighed against the learning curve necessary for some operators. This most complete analysis of the value of radial access may convince some doubters to switch.”

For more information: www.interventions.onlinejacc.org

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init